Go Pro
NASDAQ:NEUP

Neuphoria Therapeutics Q2 2025 Earnings Report

Neuphoria Therapeutics logo
$3.73 0.00 (0.00%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$3.74 +0.01 (+0.27%)
As of 09/11/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neuphoria Therapeutics EPS Results

Actual EPS
-$1.23
Consensus EPS
-$2.01
Beat/Miss
Beat by +$0.78
One Year Ago EPS
N/A

Neuphoria Therapeutics Revenue Results

Actual Revenue
$660.00 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neuphoria Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Friday, February 14, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Neuphoria Therapeutics' Q4 2026 earnings is estimated for Monday, October 5, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, September 30, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Neuphoria Therapeutics Earnings Headlines

Reviewing Moderna (NASDAQ:MRNA) and Neuphoria Therapeutics (NASDAQ:NEUP)
Neuphoria Therapeutics Inc Ordinary Shares NEUP
your job is on the list
The CEO of one of the largest AI labs on earth said it plainly: AI could wipe out half of all entry-level white-collar jobs. Another industry leader put a number on the wages shifting hands - three to twelve trillion dollars. That money does not disappear, it moves to whoever owns the machine doing the work. Dylan Jovine found the company quietly renting that machine to corporate America.tc pixel
Neuphoria Therapeutics Inc (NEUP)
See More Neuphoria Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neuphoria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuphoria Therapeutics and other key companies, straight to your email.

About Neuphoria Therapeutics

Neuphoria Therapeutics (NASDAQ:NEUP), Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

View Neuphoria Therapeutics Profile